Neonc Technologies Holdings, Inc. (NASDAQ:NTHI - Get Free Report) President Amir Heshmatpour acquired 5,000 shares of the firm's stock in a transaction on Monday, April 6th. The stock was purchased at an average price of $6.32 per share, with a total value of $31,600.00. Following the purchase, the president owned 3,017,000 shares in the company, valued at approximately $19,067,440. The trade was a 0.17% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Neonc Technologies Trading Down 3.5%
NASDAQ:NTHI opened at $5.74 on Tuesday. Neonc Technologies Holdings, Inc. has a 52 week low of $3.20 and a 52 week high of $12.99. The firm has a 50-day moving average price of $8.87 and a two-hundred day moving average price of $9.22.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the stock. Barclays PLC grew its position in shares of Neonc Technologies by 5,314.8% during the 4th quarter. Barclays PLC now owns 9,151 shares of the company's stock valued at $76,000 after acquiring an additional 8,982 shares during the period. Foundations Investment Advisors LLC bought a new position in shares of Neonc Technologies during the 3rd quarter valued at approximately $100,000. SLT Holdings LLC bought a new position in shares of Neonc Technologies during the 3rd quarter valued at approximately $100,000. Goldman Sachs Group Inc. bought a new position in shares of Neonc Technologies during the 4th quarter valued at approximately $124,000. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of Neonc Technologies during the 4th quarter valued at approximately $126,000.
Analyst Upgrades and Downgrades
NTHI has been the subject of a number of research reports. Weiss Ratings reissued a "sell (e+)" rating on shares of Neonc Technologies in a research report on Friday, March 27th. Zacks Research raised shares of Neonc Technologies to a "hold" rating in a research report on Wednesday, January 14th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Reduce".
Get Our Latest Report on NTHI
About Neonc Technologies
(
Get Free Report)
Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
